Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors

Tanya Schild; Kayvan R Keshari

doi:10.1016/j.ccell.2022.10.023

Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors

Cancer Cell. 2022 Dec 12;40(12):1457-1458. doi: 10.1016/j.ccell.2022.10.023. Epub 2022 Nov 17.

Authors

Tanya Schild¹, Kayvan R Keshari²

Affiliations

¹ Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
² Department of Radiology and Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: rahimikk@mskcc.org.

PMID: 36400017
DOI: 10.1016/j.ccell.2022.10.023

Abstract

Brain tumors are notoriously difficult to treat. Three recent Cancer Cell articles aim to uncover novel druggable targets in IDH mutant gliomas, diffuse midline gliomas, and medulloblastomas, respectively, and show that these brain tumor types shift their metabolism to become reliant on de novo pyrimidine synthesis.

Publication types

Comment

MeSH terms

Brain Neoplasms* / genetics
Brain Neoplasms* / pathology
Glioma* / pathology
Humans
Isocitrate Dehydrogenase / genetics
Mutation
Pyrimidines / pharmacology

Substances

Isocitrate Dehydrogenase
Pyrimidines